Travere Therapeutics Third Quarter 2026 Earnings Results - TRAVERE THERAPEUTICS INC

Explicit Guidance:

• Revenue: Management does not provide specific quarterly or annual numerical revenue guidance; however, they reaffirm the long-term financial target of achieving or exceeding $3 billion in annual PhilSparry sales by 2033.
• Product Sales: Projected Q4 2026 net sales for PhilSparry are expected to be reduced by approximately $8 million compared to Q3 levels, solely due to inventory normalization at specialty pharmacy partners following Q3 inventory build-up.
• Gross-to-Net: Anticipates Q4 2026 discounts to be higher than Q3; full-year 2026 gross-to-net discounts for PhilSparry are expected to be in the mid-20% range.
• Stock-Based Compensation: Q3 included $23.8 million in non-cash SBC; no specific future annualized SBC guidance provided.
• Cash Position: As of September 30, 2026, cash equivalents and marketable securities stood at $471.8 million.

Business-Segment Outlook:

• PhilSparry (IgA Nephropathy):
  • Market Dynamics: Anticipates continued strong demand but expects quarter-over-quarter variability in new patient start forms due to increased competition, expanded commercial activities from other firms, and constraints on nephrologist time.
  • Patient Segmentation: Focus on penetrating the ~70% of the IgA population with proteinuria below 1.5 g/g, a segment expected to grow with increased biopsies and earlier diagnosis.
  • Treatment Sequencing: Expects Filspari to maintain a foundational role, potentially used in combination with B-cell therapies and SGLT2s. Anticipates B-cell therapies will replace historical steroid/immunosuppressant roles, with Filspari added for kidney protection.
  • Pediatrics: Approximately 10% of FSGS start forms are pediatric (ages 8+); access and gross-to-net are consistent with adults.
  • Launch Trajectory: FSGS launch conversion to paid scripts is tracking faster than the initial IgA launch, now nearing IgA levels of conversion.
• PhilSparry (FSGS):
  • Penetration: Early use focused on higher proteinuria; expects broader utilization including lower proteinuria, genetic, secondary, and unknown cause FSGS as nephrologists gain experience.
  • Adoption: Approximately two-thirds of nephrologists who prescribed for FSGS have treated only one patient since launch; significant opportunity exists to deepen prescribing within existing practices.
  • Access: Most payers have updated coverage policies to include FSGS; expects further progress through year-end 2026.
• Pipeline (PEG-2-batinase):
  • Timeline: Targeting top-line results from the Phase 3 Harmony study in the second half of 2027.
  • Objective: Potential to become the first disease-modifying therapy for classical Homocystinuria (HCU), addressing ~7,000–10,000 U.S. patients.
• Pipeline (Sevorabrutinib):
  • Timeline: Anticipates submitting a U.S. IND by year-end 2026.
  • Development: Planning feasibility for late-stage studies; prioritizing Primary Membranous Nephropathy first, followed by immune-mediated FSGS and minimal change disease.
• Pipeline (Filspari Post-Transplant):
  • Data Release: Anticipates sharing data from the SPARCS study (evaluating Filspari in recurrent FSGS and IgA post-transplant) in 2027.
  • New Study: On track to initiate SPARlight (Phase 4) later in 2026, focusing on adult and pediatric African ancestry patients with FSGS at risk of progression.

Market and Competitive Outlook:

• Competition: Recognizes new market entrants in the IgA space but maintains confidence in Filspari as the most prescribed and preferred kidney-targeted medicine, particularly for patients with proteinuria <1.5 g/g.
• Market Evolution: Anticipates a shift from monotherapy to combination therapies (Filspari + SGLT2 + B-cell therapy) for high-risk patients to achieve complete remission and reduce residual proteinuria.
• Diagnostic Trends: Expects a growing number of patients to be diagnosed earlier and enter treatment sooner, driven by the "Kidney Care National Plan" and increased biopsy utilization.
• Payer Behavior: Anticipates payers will increasingly reimburse Filspari as a foundational therapy, even in patients initially treated with B-cell therapies, viewing it as additive rather than a switch.

Macro / Industry Outlook:

• Regulatory/Government: Views the HHS Kidney Care National Plan as a structural shift providing federal attention to rare kidney diseases, focusing on earlier detection and intervention, which serves as a long-term growth catalyst.
• Clinical Guidelines: Expect KDIGO guidelines to continue supporting the move toward earlier, more aggressive kidney-directed care (Filspari replacing RAS inhibitors), aligning with the "complete remission" treatment goal.
• Healthcare System: Anticipates that increased competition and demand for nephrologist time will create short-term variability in prescribing behavior but will not undermine the fundamental value of Filspari.

Strategic Initiatives:

• Leadership Transition: Dr. Eric Dube is stepping down as CEO in December 2026; Bradley (new CEO) joins on December 1st, 2026, to lead the company into its next chapter.
• Patent Portfolio: Strengthened with newly issued patents for IgA nephropathy and a notice of allowance for FSGS methods, extending protection terms through 2037.
• M&A/Licensing: The licensing agreement with Everest became effective during Q3; the company is advancing the Sevorabrutinib program under this collaboration.
• Commercial Expansion: Continued investment in the expanded field team to support FSGS launch and strengthen foundational positioning in IgA nephropathy.
• Access Programs: Continued use of "Quick Start" and "Bridge" programs to ensure patient access during payer formulary evaluation, with extensions now available for 12 months.

Risks and Headwinds to Outlook:

• Sales Volatility: Fourth-quarter 2026 sales are explicitly expected to dip by ~$8 million due to inventory normalization, not demand weakness.
• Market Competition: Increased commercial activities from other companies in the IgA space may cause quarter-to-quarter variability in new patient starts and physician attention.
• Clinical Execution: Risks associated with enrollment timelines and delivery of top-line data for PEG-2-batinase (Harmony study) in H2 2027 and Sevorabrutinib IND submission.
• Commercial Uncertainty: FSGS launch is still early; conversion rates and patient persistence dynamics remain to be fully observed as the launch matures.
• Regulatory/Policy: Dependence on the successful translation of the HHS National Plan into actionable clinical protocols and payer coverage changes.

Management Tone on the Future:

• Confidence Level: Described as "very pleased" and "increasingly durable," with a stated conviction that the "best days are ahead."
• Strategic Outlook: Emphasis on "excellent execution," "growing momentum," and a transition from a single-product company to a "leading rare disease company with multiple opportunities."
• Transition Sentiment: Management frames the CEO transition as occurring from a "position of strength," expressing deep confidence in the new leadership (Bradley) and the executive team's ability to build on current momentum.
• Long-term View: Strong belief in the $3 billion sales goal by 2033 and the potential for Filspari to grow beyond 2033 due to patent life and expanding patient access.

Miscellaneous:

• Patent Terms: New patents for Filspari in IgA nephropathy and FSGS extend patent life through 2037.
• Pipeline Focus: Future development of Sevorabrutinib may include additional indications beyond Primary Membranous Nephropathy, FSGS, and Minimal Change Disease, pending FDA engagement.
• Financial Metrics: Q3 Net Product Sales for Filspari reached $200.2 million; Total Revenue was $224.6 million (including $4.4M licensing revenue).